Navigation

Prostate cancer (hormone refractory) - atrasentan [ID390]

Atrasentan for hormone refractory prostate cancer

Status: Suspended
Expected date of issue: TBC
Referral date: June 2004
Process: STA
Topic area:
  • Cancer
  • Urogenital
 

NICE project team

Executive Lead: TBC
Technical Lead: TBC
Communications manager: TBC
Project manager: TBC
Assessment Group / Evidence Review Group: TBC
Top


 

Provisional schedule

Closing date for invited submissions / evidence submission: TBC
1st appraisal committee meeting: TBC
2nd appraisal committee meeting TBC
Top


 

Consultees and commentators

To be confirmed

Top


 

Project history

Date Update
27 May 2005 Topic summary published
25 August 2006 This topic was transferred to the Single technology appraisal (STA) process as part of the Institute's 12th wave work programme.
8 January 2007 Topic is suspended as the manufacturer has not applied for EMEA regulatory approval at this time
Top


 

Key documents

This page was last updated: 28 February 2012

Accessibility | Cymraeg | Freedom of information | Vision Impaired | Contact Us | Glossary | Data protection | Copyright | Disclaimer | Terms and conditions

Copyright 2014 National Institute for Health and Care Excellence. All rights reserved.

Selected, reliable information for health and social care in one place

Accessibility | Cymraeg | Freedom of information | Vision Impaired | Contact Us | Glossary | Data protection | Copyright | Disclaimer | Terms and conditions

Copyright 2014 National Institute for Health and Care Excellence. All rights reserved.